Following early work in model system genetics, Exelixis established a broad drug discovery and development platform that has served as the foundation for the company’s continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.
Please see our community guidelines: bit.ly/2XXw9w3.
To learn about us, visit www.exelixis.com/mission.
Please see our community guidelines: bit.ly/2XXw9w3.
To learn about us, visit www.exelixis.com/mission.
Location: United States, California, Alameda
Employees: 501-1000
Phone: +1 650-837-7000
Founded date: 1994
Investors 3
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| 22.09.2022 | Internatio... | ibtplc.com |
| - | Atlas Vent... | atlasventu... |
Mentions in press and media 17
| Date | Title | Description |
| 18.07.2024 | Frost & Sullivan Institute Celebrates Leaders in Sustainability with 2024 Enlightened Growth Leadership Awards | SANTA CLARA, Calif., July 18, 2024 /PRNewswire/ -- The Frost & Sullivan Institute is excited to announce the winners of the 2024 Enlightened Growth Leadership Best Practices Recognition from the Americas (LATAM and North Americas). This... |
| 13.09.2023 | Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor | — ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. ... |
| 02.11.2022 | Exelixis shells out $100M cash in a pair of deals, shooting for different takes on CD47, ADCs | Now that its cabozantinib franchise — including Cabometyx tablets and Cometriq capsules — has nestled its way into blockbuster status, Exelixis is replenishing the pipeline with some early-stage bets. The biotech revealed ... |
| 14.10.2021 | Exelixis and STORM enter into exclusive collaboration to discover and develop inhibitors of novel RNA modifying enzymes | Exelixis and STORM Therapeutics enter into exclusive collaboration and license agreement to discover and develop inhibitors of novel RNA modifying enzymes Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that the... |
| 30.06.2021 | Will Exelixis Stock See Even Lower Levels After Negative Data From A Clinical Trial? | BRAZIL - 2020/11/04: In this photo illustration the Exelixis logo seen displayed on a smartphone. ... [+] (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images |
| 04.05.2021 | Life Sciences portfolio company Gamamabs signs an agreement with Exelixis | To read the detailed press release, please click here |
| 18.03.2021 | Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Ur... | ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 18, 2021-- Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b dose escalation study ... |
| 25.02.2021 | Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer | ALAMEDA, Calif.--(BUSINESS WIRE)--Feb 25, 2021-- Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib (CABOMETYX®) as a potential treatme... |
| 08.09.2020 | News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero | Peter Lamb Catalent’s Redwood Bioscience subsidiary is taking the lead role in developing ADCs for Exelixis $EXEL. In one of 2 deals announced this morning, Exelixis is turning to Catalent to do the discovery work on th... |
| 04.09.2016 | The biotech empires of Silicon Valley and Europe | Bérénice Magistretti Contributor Bérénice Magistretti is a Swiss freelance writer based in San Francisco. She focuses on startups in Saudi Arabia, Switzerland and emerging markets. More posts by this contributor Disrupting the world of scie... |
Show more